Company: ABUS
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001447028-25-000099
Chunk: 14

Company: Arbutus Biopharma Corp
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
371,098)$(48,166)$79,157 

See accompanying notes to the condensed consolidated financial statements.

3

ARBUTUS BIOPHARMA CORPORATION

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands of U.S. Dollars, except share amounts)

Common Shares Number of SharesShare CapitalAdditional Paid-In CapitalDeficitAccumulated Other Comprehensive LossTotal Stockholders' EquityBalance December 31, 2023169,867,414 $1,349,821 $81,270 $(1,276,652)$(48,421)$106,018 Stock-based compensation expense— — 2,014 — — 2,014 Issuance of common shares pursuant to the Open Market Sale Agreement8,666,077 21,765 — — — 21,765 Issuance of common shares pursuant to exercise of options1,126,691 4,268 (1,814)— — 2,454 Issuance of common shares pursuant to ESPP121,563 271 (60)— — 211 Issuance of common shares upon vesting of RSUs410,482 1,190 (1,190)— — — Unrealized gain on available-for-sale securities— — — — 50 50 Net loss— $— $— $(17,875)$— $(17,875)Balance March 31, 2024180,192,227 1,377,315 80,220 (1,294,527)(48,371)114,637 

See accompanying notes to the condensed consolidated financial statements.

4

ARBUTUS BIOPHARMA CORPORATION

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands of U.S. Dollars)

 Three Months Ended March 31, 20252024OPERATING ACTIVITIESNet loss$(24,526)$(17,875)Non-cash items:Depreciation330 355 Loss on impairment of leasehold improvements and lab equipment2,811 — Stock-based compensation expense3,564 2,014 Change in fair value of contingent consideration299 180 Non-cash royalty revenue(448)(593)Non-cash interest expense28 36 Net accretion and amortization of investments in marketable securities(718)(